OSMR
ENSG00000145623
Target class
Unclassified protein
Chromosome
5
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- OSMR
- Gene name
- Oncostatin M receptor
- Gene symbol
- OSMR
- Protein name
- Oncostatin-M-specific receptor subunit beta (Interleukin-31 receptor subunit beta) (IL-31 receptor subunit beta) (IL-31R subunit beta) (IL-31R-beta) (IL-31RB)
- OSMRB
- OSMRbeta
- Gene biotype
- Protein coding
- Gene family
- Fibronectin type III domain containing
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 52
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 116.99
- Tissue specificity (Gini)
- 0.5
- Tissue specificity (tau)
- 0.814
- KEGG gene identifiers
- hsa:9180
- Reactome pathways
- R-HSA-6788467
- Protein interaction confidence
- 0.842586
- Protein interaction partners
- 29
- End position
- 38945596
- Start position
- 38845852
- Chromosome
- 5
- Strand
- Forward
- Membrane
- Single-pass type I membrane protein .
- Nucleoli
- Tissue specificity (tau)
- 0.814291
- Expression inequality (Gini)
- 0.499993
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 116.99
- Adipose - Visceral (Omentum)
- 72.39
- Lung
- 67.03
- Artery - Tibial
- 57.4
- Artery - Aorta
- 55.86
Expression in transcripts per million
- Cells - Cultured fibroblasts116.99
- Adipose - Visceral (Omentum)72.39
- Lung67.03
- Artery - Tibial57.4
- Artery - Aorta55.86
- Artery - Coronary55.68
- Adipose - Subcutaneous48.54
- Nerve - Tibial44.42
- Breast - Mammary Tissue42.96
- Fallopian Tube41.13
- Uterus40.32
- Cervix - Endocervix36.47
- Thyroid35.2
- Bladder35
- Adrenal Gland31.82
- Esophagus - Muscularis31.14
- Ovary30.63
- Prostate29.67
- Minor Salivary Gland29.11
- Vagina27.89
- Esophagus - Gastroesophageal Junction27.02
- Cervix - Ectocervix26.93
- Colon - Sigmoid26.57
- Spleen25.04
- Skin - Sun Exposed (Lower leg)21.46
And 29 more, listed on the interactive page.
- GO:0002675
- GO:0008284
- GO:0019221
- GO:0034097
- GO:0038165
- GO:0005886
- GO:0005900
- GO:0016324
- GO:0004924
- GO:0005515
- GO:0015026
- GO:0019838
Related records
Trials (5)
- A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
- A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
- A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
- Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
Drugs (1)
- Vixarelimab Oncostatin-M-specific receptor subunit beta inhibitor